 HOUSTON, May 12, 2021 PRNewswire -- Soliton, Inc., Nasdaq: SOLY Soliton or the Company, a medical device company with a novel and proprietary platform technology, today reported financial results for the first quarter ended March 31, 2021. Recent Company Highlights: Received FDA 510k clearance for short-term improvement in the appearance of cellulite; Selected RESONICTM as the brand name for the Companys Rapid Acoustic Pulse RAP device; Received FDA Special 510k clearance for modifications to the RESONIC device to facilitate ease of use in commercial settings; Successfully completed all required safety testing including Quality SystemCurrent Good Manufacturing Practice regulations for medical devices 21 CFR Part 820 inspection from the FDA; Expanded sales team through appointment of Sean J. 